Navigation Links
FDA to Communicate Safety Monitoring Activities to Consumers and Health Care Professionals
Date:6/15/2010

New website will contain safety reports on recently approved drugs, biologics

SILVER SPRING, Md., June 15 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Summaries of FDA safety analyses on recently approved products will now be periodically prepared and posted on FDA's website along with a brief discussion of the steps FDA is taking to address any identified safety issues.

Some side effects may not become apparent until after a medicine has been approved and becomes available to a larger, more diverse population than the patients who participated in clinical trials that supported approval. The new summaries provide a comprehensive look at safety data early in the product's post-approval life cycle and are based on reports by manufacturers, providers, consumers and others to the FDA's Adverse Event Reporting System (AERS) and the Vaccine Adverse Event Reporting System maintained by the FDA and the Center for Disease Control and Prevention; periodic safety information submitted to FDA by manufacturers; information contained in the medical literature; and data from ongoing drug and biologic studies.

Included in the summaries may be information on potentially serious, previously unidentified risks, if any are found during the review, as well as known adverse events that occur more often than they did during clinical studies. The summaries will also include a brief discussion of any steps FDA may be taking to address these safety issues.

Under Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), FDA is required to prepare the safety summaries within 18 months after a product's approval or after it has been used by 10,000 patients, whichever comes later.

"Conducting systematic, comprehensive, safety reviews of recently approved drugs and biologics provides an early detection mechanism for potentially serious risks and complements the FDA's analysis of safety data during drug development and the agency's routine monitoring of safety information after product approval," said Gerald Dal Pan, M.D., M.H.S., director of the Office of Surveillance and Epidemiology in the FDA's Center for Drug Evaluation and Research.

"These summaries will provide clear and useful information in a timely manner that can be used by providers and patients to make informed decisions about an individual's health," said Robert Ball, M.D., M.P.H., Sc.M., director of the Office of Biostatistics and Epidemiology in the Center for Biologics Evaluation and Research.

Initial summary reports will contain information on drugs and biologics approved since September 2007, including several drugs for infections, hypertension, depression and other conditions. The summary reports will be located on an FDA Web page that was first established in 2008 to serve as a portal for drug safety information.

For more information

Postmarketing Drug Safety Evaluation

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm204091.htm

Medwatch: What is a Serious Adverse Event?

http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm

Office of Surveillance and Epidemiology (OSE)

http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm106491.htm

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK Premieres Safety System at DIA
2. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
3. FDA Consumer Health Information - FDAs MedWatch Safety Alerts: May 2010
4. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
5. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
6. ExpertRECALL Awards First Scholarships for Product-Safety Education
7. JCR and Hill-Rom Name Nurse Safety Scholar-in-Residence
8. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
9. Improving Safety While Advancing the Pharmacy Technician Profession
10. FDA CONSUMER HEALTH INFORMATION - FDAs MedWatch Safety Alerts: April 2010
11. New Data Reinforces the Proven Safety and Effectiveness of the BIRMINGHAM HIP Resurfacing System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants totaling ... as part of its prestigious Bayer Hemophilia Awards Program (BHAP). ... Philadelphia and Uniformed Services University of ... among the winners. Grant recipients were announced last night during ... (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... of Echenberg Institute, is announcing a new safe and effective at-home VuVa ... other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, vulvar ... ... VuVa ... company, VuVatech LLC, fills a void in the women,s wellness market because ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Team Novo Nordisk, ... Brand to the men’s pro squad as a stagiaire for the remainder of the ... professional debut on July 31st at the Tour of Utah. , “Every season we ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. ... advancement in drug therapy for patients living with relapsing and primary multiple sclerosis ... B cell targeted therapy that has been proven to significantly reduce signs of ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we ... from San Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending ... orthodontic braces. In doing so, it offers an effective alternative to traditional braces. As ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... “We are ... offer the ability for patients to schedule an appointment online in real time,” said ... the Six Month Smiles provider directory will bring more Six Month Smiles patients to ...
Breaking Medicine News(10 mins):